The FDA announced on 2022-12-16 that Aurolife Pharma, LLC is recalling Glycopyrrolate Tablets, USP, 1 mg due to failed impurity specifications. The recall affects lots distributed nationwide.
How to tell if you have it
- Brand: Aurolife
- Product: Glycopyrrolate Tablets, USP, 1 mg, 100 tablets, Rx Only
- Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ
- NDC: 13107-014-01
- Lots: 01422002A1 (Expiry: 12/2023), 01421078A3 (Expiry: 09/2023)
- Quantity: 7344 bottles
- Distribution: Nationwide in the USA and Puerto Rico
The hazard
The tablets failed impurity specifications, according to the FDA. The agency classified the recall as Class II.
Context
GovInfoNow's records show Aurolife Pharma, LLC has 3 other recalls on record since 2019-08-23. Other recent recalls of similar products include Novadoz Glycopyrrolate Oral Solution Recall (2025-12-15), Precision Dose Glycopyrrolate Oral Solution Recall (2026-07-14), and Glenmark Alyacen Birth Control Tablets Recall (2026-05-27).